PTPN11 in cartilage development, adult homeostasis, and diseases

Abstract

The SH2 domain-containing protein tyrosine phosphatase 2 (SHP2, also known as PTP2C), encoded by PTPN11, is ubiquitously expressed and has context-specific effects. It promotes RAS/MAPK signaling downstream of receptor tyrosine kinases, cytokine receptors, and extracellular matrix proteins, and was shown in various lineages to modulate cell survival, proliferation, differentiation, and migration. Over the past decade, PTPN11 inactivation in chondrocytes was found to cause metachondromatosis, a rare disorder characterized by multiple enchondromas and osteochondroma-like lesions. Moreover, SHP2 inhibition was found to mitigate osteoarthritis pathogenesis in mice, and abundant but incomplete evidence suggests that SHP2 is crucial for cartilage development and adult homeostasis, during which its expression and activity are tightly regulated transcriptionally and posttranslationally, and by varying sets of functional partners. Fully uncovering SHP2 actions and regulation in chondrocytes is thus fundamental to understanding the mechanisms underlying both rare and common cartilage diseases and to designing effective disease treatments. We here review current knowledge, highlight recent discoveries and controversies, and propose new research directions to answer remaining questions.

Keywords

Biological Sciences / Biochemistry and Cell Biology

References

[1] PacificiM, et al. . Cellular and molecular mechanisms of synovial joint and articular cartilage formation. Ann. N. Y. Acad. Sci., 2006, 1068: 74-86.

[2] KozhemyakinaE, LassarAB, ZelzerE. A pathway to bone: signaling molecules and transcription factors involved in chondrocyte development and maturation. Development, 2015, 142: 817-831.

[3] GoldringMB, TsuchimochiK, IjiriK. The control of chondrogenesis. J. Cell Biochem., 2006, 97: 33-44.

[4] KronenbergHM. Developmental regulation of the growth plate. Nature, 2003, 423: 332-336.

[5] BallockRT, O’KeefeRJ. The biology of the growth plate. J. Bone Jt. Surg. Am., 2003, 85-A: 715-726.

[6] Ulrich-VintherM, MaloneyMD, SchwarzEM, RosierR, O’KeefeRJ. Articular cartilage biology. J. Am. Acad. Orthop. Surg., 2003, 11: 421-430.

[7] Roseti, L., Desando, G., Cavallo, C., Petretta, M. & Grigolo, B. Articular cartilage regeneration in osteoarthritis. Cells8, 1305 (2019).

[8] LefebvreV, AngelozziM, HaseebA. SOX9 in cartilage development and disease. Curr. Opin. Cell Biol., 2019, 61: 39-47.

[9] SamsaWE, ZhouX, ZhouG. Signaling pathways regulating cartilage growth plate formation and activity. Semin Cell Dev. Biol., 2017, 62: 3-15.

[10] RuxD, DeckerRS, KoyamaE, PacificiM. Joints in the appendicular skeleton: developmental mechanisms and evolutionary influences. Curr. Top. Dev. Biol., 2019, 133: 119-151.

[11] LimJ, et al. . BMP-Smad4 signaling is required for precartilaginous mesenchymal condensation independent of Sox9 in the mouse. Dev. Biol., 2015, 400: 132-138.

[12] OrnitzDM. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev., 2005, 16: 205-213.

[13] ZuscikMJ, HiltonMJ, ZhangX, ChenD, O’KeefeRJ. Regulation of chondrogenesis and chondrocyte differentiation by stress. J. Clin. Investig., 2008, 118: 429-438.

[14] SongH, ParkKH. Regulation and function of SOX9 during cartilage development and regeneration. Semin. Cancer Biol., 2020, 67: 12-23.

[15] AgirdilY. The growth plate: a physiologic overview. EFORT Open Rev., 2020, 5: 498-507.

[16] WangL, et al. . SHP2 regulates the osteogenic fate of growth plate hypertrophic chondrocytes. Sci. Rep., 2017, 7. 12699

[17] HoubenA, et al. . β-catenin activity in late hypertrophic chondrocytes locally orchestrates osteoblastogenesis and osteoclastogenesis. Development, 2016, 143: 3826-3838.

[18] YangL, TsangKY, TangHC, ChanD, CheahKS. Hypertrophic chondrocytes can become osteoblasts and osteocytes in endochondral bone formation. Proc. Natl. Acad. Sci. USA, 2014, 111: 12097-12102.

[19] ZhouX, et al. . Chondrocytes transdifferentiate into osteoblasts in endochondral bone during development, postnatal growth and fracture healing in mice. PLoS Genet., 2014, 10: e1004820.

[20] PacificiM, KoyamaE, IwamotoM. Mechanisms of synovial joint and articular cartilage formation: recent advances, but many lingering mysteries. Birth Defects Res. Part C. Embryo Today Rev., 2005, 75: 237-248.

[21] KozhemyakinaE, et al. . Identification of a Prg4-expressing articular cartilage progenitor cell population in mice. Arthritis Rheumatol., 2015, 67: 1261-1273.

[22] LiL, et al. . Superficial cells are self-renewing chondrocyte progenitors, which form the articular cartilage in juvenile mice. FASEB J., 2017, 31: 1067-1084.

[23] KoyamaE, et al. . A distinct cohort of progenitor cells participates in synovial joint and articular cartilage formation during mouse limb skeletogenesis. Dev. Biol., 2008, 316: 62-73.

[24] RountreeRB, et al. . BMP receptor signaling is required for postnatal maintenance of articular cartilage. PLoS Biol., 2004, 2: e355.

[25] YangH, WangL, ShigleyC, YangW. Protein tyrosine phosphatases in skeletal development and diseases. Bone Res., 2022, 10: 10.

[26] OrnitzDM, MariePJ. Fibroblast growth factors in skeletal development. Curr. Top. Dev. Biol., 2019, 133: 195-234.

[27] Kim, J. M. et al. The ERK MAPK pathway is essential for skeletal development and homeostasis. Int. J. Mol. Sci.20, 1803 (2019).

[28] SegalinyAI, Tellez-GabrielM, HeymannMF, HeymannD. Receptor tyrosine kinases: characterisation, mechanism of action and therapeutic interests for bone cancers. J. Bone Oncol., 2015, 4: 1-12.

[29] OrnitzDM, MariePJ. Fibroblast growth factor signaling in skeletal development and disease. Genes Dev., 2015, 29: 1463-1486.

[30] LahiryP, TorkamaniA, SchorkNJ, HegeleRA. Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat. Rev. Genet., 2010, 11: 60-74.

[31] Chan, G. & Neel, B. G. Role of PTPN11 (SHP2) in cancer. in Protein Tyrosine Phosphatases in Cancer (ed. Neel B., T. N.) (Springer, 2016).

[32] FengGS. Shp2-mediated molecular signaling in control of embryonic stem cell self-renewal and differentiation. Cell Res., 2007, 17: 37-41.

[33] NeelB. Structure and function of SH2-domain containing tyrosine phosphatases. Semin. Cell Biol., 1993, 4: 419-432.

[34] BoboneS, et al. . Targeting oncogenic Src homology 2 Domain-Containing Phosphatase 2 (SHP2) by inhibiting its protein-protein interactions. J. Med. Chem., 2021, 64: 15973-15990.

[35] HofP, PluskeyS, Dhe-PaganonS, EckMJ, ShoelsonSE. Crystal structure of the tyrosine phosphatase SHP-2. Cell, 1998, 92: 441-450.

[36] SaxtonT, et al. . Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J., 1997, 16: 2352-2364.

[37] YangW, et al. . An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. Dev. Cell, 2006, 10: 317-327.

[38] ChenJ, et al. . SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood, 2007, 109: 778-785.

[39] Gu, S. et al. SHP2 is required for BCR-ABL1-induced hematologic neoplasia. Leukemia, 32, 203–213 (2017).

[40] MitraS, BeachC, FengGS, PlattnerR. SHP-2 is a novel target of Abl kinases during cell proliferation. J. Cell Sci., 2008, 121: 3335-3346.

[41] MohiMG, et al. . Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell, 2005, 7: 179-191.

[42] ArakiT, NawaH, NeelBG. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J. Biol. Chem., 2003, 278: 41677-41684.

[43] BennettAM, TangTL, SugimotoS, WalshCT, NeelBG. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc. Natl. Acad. Sci. USA, 1994, 91: 7335-7339.

[44] YamauchiK, MilarskiKL, SaltielAR, PessinJE. Protein-tyrosine-phosphatase SHPTP2 is a required positive effector for insulin downstream signaling. Proc. Natl. Acad. Sci. USA, 1995, 92: 664-668.

[45] YartA, et al. . A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. J. Biol. Chem., 2001, 276: 8856-8864.

[46] LuW, GongD, Bar-SagiD, ColePA. Site-Specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol. Cell, 2001, 8: 759-769.

[47] StrackV, et al. . The Protein-tyrosine-phosphatase SHP2 is phosphorylated on serine residues 576 and 591 by protein kinase C isoforms alpha, beta 1, beta 2, and eta. Biochemistry, 2002, 41: 603-608.

[48] MohiMG, NeelBG. The role of Shp2 (PTPN11) in cancer. Curr. Opin. Genet. Dev., 2007, 17: 23-30.

[49] Neel, B. G., Chan G. & Dhanji S. SH2 domain-containing protein-tyrosine phosphatases. Handbook of Cell Signaling (Academic press, 2009).

[50] JarvisLA, ToeringSJ, SimonMA, KrasnowMA, Smith-BoltonRK. Sprouty proteins are in vivo targets of Corkscrew/SHP-2 tyrosine phosphatases. Development, 2006, 133: 1133-1142.

[51] HanafusaH, ToriiS, YasunagaT, MatsumotoK, NishidaE. Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. J. Biol. Chem., 2004, 279: 22992-22995.

[52] DanceM, MontagnerA, SallesJP, YartA, RaynalP. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal., 2008, 20: 453-459.

[53] SimanshuDK, MorrisonDK. A structure is worth a thousand words: new insights for RAS and RAF regulation. Cancer Discov., 2022, 12: 899-912.

[54] AgazieYM, HaymanMJ. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol. Cell Biol., 2003, 23: 7875-7886.

[55] ZhangSQ, et al. . Receptor-specific regulation of phosphatidylinositol 3’-kinase activation by the protein tyrosine phosphatase Shp2. Mol. Cell Biol., 2002, 22: 4062-4072.

[56] WuCJ, et al. . The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene, 2001, 20: 6018-6025.

[57] GuoW, et al. . Tyrosine phosphatase SHP2 negatively regulates NLRP3 inflammasome activation via ANT1-dependent mitochondrial homeostasis. Nat. Commun., 2017, 8. 2168

[58] SalviM, et al. . Tyrosine phosphatase activity in mitochondria: presence of Shp-2 phosphatase in mitochondria. Cell. Mol. Life Sci., 2004, 61: 2393-2404.

[59] GaoJ, et al. . Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis. J. Hepatol., 2020, 73: 1144-1154.

[60] TartagliaM, et al. . Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet., 2003, 34: 148-150.

[61] TartagliaM, NiemeyerCM, ShannonKM, LohML. SHP-2 and myeloid malignancies. Curr. Opin. Hematol., 2004, 11: 44-50.

[62] KontaridisMI, et al. . Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways. Circulation, 2008, 117: 1423-1435.

[63] TartagliaM, et al. . Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet., 2001, 29: 465-468.

[64] DigilioMC, et al. . Familial aggregation of genetically heterogeneous hypertrophic cardiomyopathy: a boy with LEOPARD syndrome due to PTPN11 mutation and his nonsyndromic father lacking PTPN11 mutations. Birth Defects Res. A Clin. Mol. Teratol., 2004, 70: 95-98.

[65] BowenME, et al. . Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome. PLoS Genet., 2011, 7: e1002050.

[66] GrossmannKS, RosarioM, BirchmeierC, BirchmeierW. The tyrosine phosphatase Shp2 in development and cancer. Adv. Cancer Res., 2010, 106: 53-89.

[67] RobertsAE, AllansonJE, TartagliaM, GelbBD. Noonan syndrome. Lancet, 2013, 381: 333-342.

[68] SarkozyA, DigilioMC, DallapiccolaB. Leopard syndrome. Orphanet J. Rare Dis., 2008, 3. 13

[69] Keilhack, H., David, F. S., McGregor, M., Cantley, L. C. & Neel, B. G. Diverse biochemical properties of Shp2 mutants: implications for disease phenotypes. J. Biol. Chem.280, 30984–30993 (2005).

[70] TartagliaM, et al. . Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am. J. Hum. Genet., 2006, 78: 279-290.

[71] LegiusE, et al. . PTPN11 mutations in LEOPARD syndrome. J. Med. Genet., 2002, 39: 571-574.

[72] GrantAR, et al. . Assessing the gene-disease association of 19 genes with the RASopathies using the ClinGen gene curation framework. Hum. Mutat., 2018, 39: 1485-1493.

[73] Tajan, M. et al. Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth. Human Mol. Genet.27, 2276–2289 (2018).

[74] MarinTM, et al. . Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J. Clin. Invest., 2011, 121: 1026-1043.

[75] TajanM, et al. . LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity. Proc. Natl. Acad. Sci. USA, 2014, 111: E4494-E4503.

[76] PapadopoulouA, BountouviE. Skeletal defects and bone metabolism in Noonan, Costello and cardio-facio-cutaneous syndromes. Front. Endocrinol., 2023, 14: 1231828.

[77] FowlkesJL, ThrailkillKM, BunnRC. RASopathies: the musculoskeletal consequences and their etiology and pathogenesis. Bone, 2021, 152: 116060.

[78] TajanM, PaccoudR, BrankaS, EdouardT, YartA. The RASopathy family: consequences of germline activation of the RAS/MAPK pathway. Endocr. Rev., 2018, 39: 676-700.

[79] KennedyLA. Metachondromatosis. Radiology, 1983, 148: 117-118.

[80] PansuriyaTC, KroonHM, BoveeJV. Enchondromatosis: insights on the different subtypes. Int. J. Clin. Exp. Pathol., 2010, 3: 557-569

[81] BoveeJV. Multiple osteochondromas. Orphanet J. Rare Dis., 2008, 3. 3

[82] MavrogenisAF, SkarpidiE, PapakonstantinouO, PapagelopoulosPJ. Chondrosarcoma in metachondromatosis: a case report. J. Bone Jt. Surg. Am., 2010, 92: 1507-1513.

[83] SobreiraNL, et al. . Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene. PLoS Genet., 2010, 6: e1000991.

[84] ChanG, KalaitzidisD, NeelBG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev., 2008, 27: 179-192.

[85] LiS, HsuDD, WangH, FengGS. Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis. Front. Med., 2012, 6: 275-279.

[86] Bard-ChapeauEA, et al. . Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell, 2011, 19: 629-639.

[87] YangW, NeelBG. From an orphan disease to a generalized molecular mechanism: PTPN11 loss-of-function mutations in the pathogenesis of metachondromatosis. Rare Dis., 2013, 1: e26657.

[88] ShapiroF, HoltropME, GlimcherMJ. Organization and cellular biology of the perichondrial ossification groove of ranvier: a morphological study in rabbits. J. Bone Jt. Surg. Am., 1977, 59: 703-723.

[89] BoveeJV, HogendoornPC, WunderJS, AlmanBA. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat. Rev. Cancer, 2010, 10: 481-488.

[90] YangW, et al. . Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. Nature, 2013, 499: 491-495.

[91] ZuoC, et al. . SHP2 regulates skeletal cell fate by modifying SOX9 expression and transcriptional activity. Bone Res., 2018, 6: 12.

[92] BowenME, AyturkUM, KurekKC, YangW, WarmanML. SHP2 regulates chondrocyte terminal differentiation, growth plate architecture and skeletal cell fates. PLoS Genet., 2014, 10: e1004364.

[93] Wang, L. et al. SHP2 ablation mitigates osteoarthritic cartilage degeneration by promoting chondrocyte anabolism through SOX9. FASEB J.38, e70013 (2024).

[94] Kim, H. K., Feng, G. S., Chen, D., King, P. D. & Kamiya, N. Targeted disruption of Shp2 in chondrocytes leads to metachondromatosis with multiple cartilaginous protrusions. J. Bone Miner. Res.29, 761–769 (2013).

[95] MiahSMS, et al. . Ptpn11 deletion in CD4⁺ cells does not affect T cell development and functions but causes cartilage tumors in a T cell-independent Manner. Front. Immunol., 2017, 8: 1326.

[96] McNamaraJT, HuntingtonKE, BorysS, JayasuriyaCT, BrossayL. SHP-2 deletion in CD4Cre expressing chondrocyte precursors leads to tumor development with wrist tropism. Sci. Rep., 2021, 11. 20006

[97] OrnitzDM, MariePJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev., 2002, 16: 1446-1465.

[98] PogueR, LyonsK. BMP signaling in the cartilage growth plate. Curr. Top. Dev. Biol., 2006, 76: 1-48.

[99] LiuJP, BakerJ, PerkinsAS, RobertsonEJ, EfstratiadisA. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell, 1993, 75: 59-72

[100] DayTF, YangY. Wnt and hedgehog signaling pathways in bone development. J. Bone Jt. Surg. Am., 2008, 90: 19-24.

[101] FengGS. Shp-2 tyrosine phosphatase: signaling one cell or many. Exp. Cell Res., 1999, 253: 47-54.

[102] RauenKA. The RASopathies. Annu. Rev. Genom. Hum. Genet., 2013, 14: 355-369.

[103] St-JacquesB, HammerschmidtM, McMahonAP. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev., 1999, 13: 2072-2086.

[104] Shao, F. et al. Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis. Nat. Commun.12, 6540 (2021).

[105] SaxtonTM, et al. . The SH2 tyrosine phosphatase shp2 is required for mammalian limb development. Nat. Genet., 2000, 24: 420-423.

[106] LoganM, et al. . Expression of Cre recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis, 2002, 33: 77-80.

[107] LapinskiPE, MeyerMF, FengGS, KamiyaN, KingPD. Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity and calvarial defects in mice. Dis. Model Mech., 2013, 6: 1448-1458

[108] Kim, H. K. et al. Induction of SHP2-deficiency in chondrocytes causes severe scoliosis and kyphosis in mice. Spine38, E1307–E1312 (2013).

[109] GebhardS, et al. . Specific expression of Cre recombinase in hypertrophic cartilage under the control of a BAC-Col10a1 promoter. Matrix Biol., 2008, 27: 693-699.

[110] Haseeb, A. et al. SOX9 keeps growth plates and articular cartilage healthy by inhibiting chondrocyte dedifferentiation/osteoblastic redifferentiation. Proc. Natl. Acad. Sci. USA118, e2019152118 (2021).

[111] Liu, Q. et al. SHP2 inhibition attenuates osteoarthritis by maintaining homeostasis of cartilage metabolism via the DOK1/UPP1/uridine cascade. Arthr. Rheumatol.74, 462–474 (2021).

[112] TaoT, et al. . Src Homology 2 domain-containing protein tyrosine phosphatase promotes inflammation and accelerates osteoarthritis by activating beta-catenin. Front. Cell Dev. Biol., 2021, 9. 646386

[113] NeelBG, GuH, PaoL. The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci., 2003, 28: 284-293.

[114] MinooP, et al. . The adaptor function of SHP-2 downstream of the prolactin receptor is required for the recruitment of p29, a substrate of SHP-2. Cell Signal., 2003, 15: 319-326.

[115] SunZ, et al. . Targeting macrophagic SHP2 for ameliorating osteoarthritis via TLR signaling. Acta Pharm. Sin. B, 2022, 12: 3073-3084.

[116] Wang, L. et al. A ERK/RSK-mediated negative feedback loop regulates M-CSF-evoked PI3K/AKT activation in macrophages. FASEB J.32, 875 (2017).

[117] MashimaR, HishidaY, TezukaT, YamanashiY. The roles of Dok family adapters in immunoreceptor signaling. Immunol. Rev., 2009, 232: 273-285.

[118] CarpinoN, et al. . p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell, 1997, 88: 197-204.

[119] DongS, et al. . T cell receptor for antigen induces linker for activation of T cell-dependent activation of a negative signaling complex involving Dok-2, SHIP-1, and Grb-2. J. Exp. Med., 2006, 203: 2509-2518.

[120] YamanashiY, BaltimoreD. Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, Dok. Cell, 1997, 88: 205-211.

[121] ZhaoM, JanasJA, NikiM, PandolfiPP, Van AelstL. Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathways to inhibit platelet-derived growth factor-induced mitogenesis. Mol. Cell Biol., 2006, 26: 2479-2489.

[122] BergKL, SiminovitchKA, StanleyER. SHP-1 regulation of p62(DOK) tyrosine phosphorylation in macrophages. J. Biol. Chem., 1999, 274: 35855-35865.

[123] LingY, MaileLA, Badley-ClarkeJ, ClemmonsDR. DOK1 mediates SHP-2 binding to the alphaVbeta3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells. J. Biol. Chem., 2005, 280: 3151-3158.

[124] Zhu, P. et al. An Integrated Proteomic Strategy to Identify SHP2 Substrates. J. Proteome Res. 21, 2515–2525 (2022).

[125] VerheyenEM, GottardiCJ. Regulation of Wnt/beta-catenin signaling by protein kinases. Dev. Dyn., 2010, 239: 34-44.

[126] BrembeckFH, et al. . Essential role of BCL9-2 in the switch between beta-catenin’s adhesive and transcriptional functions. Genes Dev., 2004, 18: 2225-2230.

[127] DaughertyRL, GottardiCJ. Phospho-regulation of Beta-catenin adhesion and signaling functions. Physiology, 2007, 22: 303-309.

[128] YostC, et al. . The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev., 1996, 10: 1443-1454.

[129] LiuC, et al. . Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell, 2002, 108: 837-847.

[130] YouM, FlickLM, YuD, FengGS. Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor. J. Exp. Med., 2001, 193: 101-110.

[131] LeePP, et al. . A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity, 2001, 15: 763-774.

[132] SawadaS, ScarboroughJD, KilleenN, LittmanDR. A lineage-specific transcriptional silencer regulates CD4 gene expression during T lymphocyte development. Cell, 1994, 77: 917-929.

[133] NguyenTV, KeY, ZhangEE, FengGS. Conditional deletion of Shp2 tyrosine phosphatase in thymocytes suppresses both pre-TCR and TCR signals. J. Immunol., 2006, 177: 5990-5996.

[134] GuittardG, et al. . Unexpected cartilage phenotype in CD4-Cre-Conditional SOS-Deficient Mice. Front. Immunol., 2017, 8: 343.

[135] WehenkelM, et al. . Extracellular signal-regulated kinase signaling in CD4-expressing cells inhibits osteochondromas. Front. Immunol., 2017, 8: 482.

[136] Yang, H., Wang, L., Turajane, K., Wang, L. & Yang, W. A method for colocalizing lineage tracing reporter and RNAscope signals on skeletal tissue section. RNA27, 359–365 (2020).

[137] Wang, L. et al. Targeted Ptpn11 deletion in mice reveals the essential role of SHP2 in osteoblast differentiation and skeletal homeostasis. Bone Res.9, 6 (2021).

[138] LiuJA, et al. . Phosphorylation of Sox9 is required for neural crest delamination and is regulated downstream of BMP and canonical Wnt signaling. Proc. Natl. Acad. Sci. USA, 2013, 110: 2882-2887.

[139] HuangW, ZhouX, LefebvreV, de CrombruggheB. Phosphorylation of SOX9 by cyclic AMP-dependent protein kinase A enhances SOX9’s ability to transactivate a Col2a1 chondrocyte-specific enhancer. Mol. Cell Biol., 2000, 20: 4149-4158.

[140] MalkiS, et al. . Prostaglandin D2 induces nuclear import of the sex-determining factor SOX9 via its cAMP-PKA phosphorylation. EMBO J., 2005, 24: 1798-1809.

[141] TaylorKM, LabonneC. SoxE factors function equivalently during neural crest and inner ear development and their activity is regulated by SUMOylation. Dev. Cell, 2005, 9: 593-603.

[142] OhHJ, KidoT, LauYF. PIAS1 interacts with and represses SOX9 transactivation activity. Mol. Reprod. Dev., 2007, 74: 1446-1455.

[143] LefebvreV, Dvir-GinzbergM. SOX9 and the many facets of its regulation in the chondrocyte lineage. Connect Tissue Res., 2017, 58: 2-14.

[144] HuangW, ChungUI, KronenbergHM, de CrombruggheB. The chondrogenic transcription factor Sox9 is a target of signaling by the parathyroid hormone-related peptide in the growth plate of endochondral bones. Proc. Natl. Acad. Sci. USA, 2001, 98: 160-165.

[145] LeeJY, et al. . Pre-transplantational control of the post-transplantational fate of human pluripotent stem cell-derived cartilage. Stem Cell Rep., 2018, 11: 440-453.

[146] CohenP, CrossD, JannePA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat. Rev. Drug Discov., 2021, 20: 551-569.

[147] WhyteJL, SmithAA, HelmsJA. Wnt signaling and injury repair. Cold Spring Harb. Perspect. Biol., 2012, 4: a008078.

[148] NevesVC, BabbR, ChandrasekaranD, SharpePT. Promotion of natural tooth repair by small molecule GSK3 antagonists. Sci. Rep., 2017, 7. 39654

[149] ChenYN, et al. . Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature, 2016, 535: 148-152.

[150] SunZ, et al. . Intraarticular injection of SHP2 inhibitor SHP099 promotes the repair of rabbit full-thickness cartilage defect. J. Orthop. Transl., 2022, 32: 112-120

[151] WangM, LuJ, WangM, YangCY, WangS. Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 Protein. J. Med. Chem., 2020, 63: 7510-7528.

[152] ArrandaleJM, et al. . Insulin signaling in mice expressing reduced levels of Syp. J. Biol. Chem., 1996, 271: 21353-21358.

[153] ZhangEE, ChapeauE, HagiharaK, FengGS. Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism. Proc. Natl. Acad. Sci. USA, 2004, 101: 16064-16069.

[154] Bauler, T. J. et al. Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations. Dis. Models Mecha.4, 228–239 (2011).

[155] Zhou, Y. et al. SHP2 regulates osteoclastogenesis by promoting preosteoclast fusion. FASEB J.29, 1635 (2015).

[156] BhowmickNA, et al. . TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science, 2004, 303: 848-851.

[157] NakamuraT, GulickJ, ColbertMC, RobbinsJ. Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development. Proc. Natl. Acad. Sci. USA, 2009, 106: 11270-11275.

[158] ArakiT, et al. . Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat. Med., 2004, 10: 849-857.

[159] NakamuraT, GulickJ, PrattR, RobbinsJ. Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations. Proc. Natl. Acad. Sci. USA, 2009, 106: 15436-15441.

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(R21 AR081642 (W.Y.))

RIGHTS & PERMISSIONS

The Author(s)